BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10614727)

  • 1. Antigen-antibody complex as therapeutic vaccine for viral hepatitis B.
    Wen YM; Qu D; Zhou SH
    Int Rev Immunol; 1999; 18(3):251-8. PubMed ID: 10614727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Advances on antigen-antibody immunogenic complex therapeutic vaccine for viral hepatitis B].
    Wang XY; Yao X; Guo LM; Xu LF; Shen XL; Xu DZ; Zhao K; Wen YM
    Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):718-20. PubMed ID: 19785971
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice.
    Zheng BJ; Ng MH; He LF; Yao X; Chan KW; Yuen KY; Wen YM
    Vaccine; 2001 Jul; 19(30):4219-25. PubMed ID: 11457548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
    Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
    Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings.
    Xu DZ; Wang XY; Shen XL; Gong GZ; Ren H; Guo LM; Sun AM; Xu M; Li LJ; Guo XH; Zhen Z; Wang HF; Gong HY; Xu C; Jiang N; Pan C; Gong ZJ; Zhang JM; Shang J; Xu J; Xie Q; Wu TF; Huang WX; Li YG; Xu J; Yuan ZH; Wang B; Zhao K; Wen YM;
    J Hepatol; 2013 Sep; 59(3):450-6. PubMed ID: 23669281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HBV DNA vaccine with adjuvant cytokines induced specific immune responses against HBV infection.
    Du DW; Jia ZS; Li GY; Zhou YY
    World J Gastroenterol; 2003 Jan; 9(1):108-11. PubMed ID: 12508362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice.
    Zhang TY; Guo XR; Wu YT; Kang XZ; Zheng QB; Qi RY; Chen BB; Lan Y; Wei M; Wang SJ; Xiong HL; Cao JL; Zhang BH; Qiao XY; Huang XF; Wang YB; Fang MJ; Zhang YL; Cheng T; Chen YX; Zhao QJ; Li SW; Ge SX; Chen PJ; Zhang J; Yuan Q; Xia NS
    Gut; 2020 Feb; 69(2):343-354. PubMed ID: 30926653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of plasmid DNA on immunogenicity of HBsAg-anti-HBs complex.
    Qu D; Yuan ZH; He LF; Yang L; Li GD; Wen YM
    Viral Immunol; 1998; 11(2):65-72. PubMed ID: 9765028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes.
    McCluskie MJ; Wen YM; Di Q; Davis HL
    Viral Immunol; 1998; 11(4):245-52. PubMed ID: 10189191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
    Zhou C; Peng G; Jin X; Tang J; Chen Z
    Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice.
    Oka Y; Akbar SM; Horiike N; Joko K; Onji M
    Immunology; 2001 May; 103(1):90-7. PubMed ID: 11380696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma.
    Böcher WO; Herzog-Hauff S; Schlaak J; Meyer zum Büschenfeld KH; Löhr HF
    Hepatology; 1999 Jan; 29(1):238-44. PubMed ID: 9862872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Suppression of the antigen-specific T cell immune response by co-immunization with the HBV DNA vaccine and recombinant HBsAg].
    Du X; Wang J; Kang Y; Xiao W; Zhao G; Wang B
    Wei Sheng Wu Xue Bao; 2009 Jul; 49(7):938-42. PubMed ID: 19873759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole recombinant Hansenula polymorpha expressing hepatitis B virus surface antigen (yeast-HBsAg) induces potent HBsAg-specific Th1 and Th2 immune responses.
    Bian G; Cheng Y; Wang Z; Hu Y; Zhang X; Wu M; Chen Z; Shi B; Sun S; Shen Y; Chen EJ; Yao X; Wen Y; Yuan Z
    Vaccine; 2009 Dec; 28(1):187-94. PubMed ID: 19789093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies.
    Weeratna RD; Brazolot Millan CL; McCluskie MJ; Siegrist CA; Davis HL
    FEMS Immunol Med Microbiol; 2001 Apr; 30(3):241-7. PubMed ID: 11335145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients.
    Yao X; Zheng B; Zhou J; Xu DZ; Zhao K; Sun SH; Yuan ZH; Wen YM
    Vaccine; 2007 Feb; 25(10):1771-9. PubMed ID: 17224217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cloning, protein expression and immunogenicity of HBs-murine IL-18 fusion DNA vaccine.
    Channarong S; Mitrevej A; Sinchaipanid N; Usuwantim K; Kulkeaw K; Chaicumpa W
    Asian Pac J Allergy Immunol; 2007 Dec; 25(4):233-42. PubMed ID: 18402297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients.
    Zhou C; Li C; Gong GZ; Wang S; Zhang JM; Xu DZ; Guo LM; Ren H; Xu M; Xie Q; Pan C; Xu J; Hu Z; Geng S; Zhou X; Wang X; Zhou X; Mi H; Zhao G; Yu W; Wen YM; Huang L; Wang XY; Wang B
    Hum Vaccin Immunother; 2017 Sep; 13(9):1989-1996. PubMed ID: 28665747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breaking B and T cell tolerance using cationic lipid--DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV.
    Morrey JD; Motter NE; Chang S; Fairman J
    Antiviral Res; 2011 Jun; 90(3):227-30. PubMed ID: 21545812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the immunogenicity of hepatitis B virus S gene variants by DNA immunization.
    Wu L; Yuan ZH; Liu F; Waters JA; Wen YM
    Viral Immunol; 2001; 14(4):359-67. PubMed ID: 11792065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.